Clinical study to investigate safety and efficacy on combination of gemcitabine and autologous gamma/delta T cell transfer therapy after resection of pancreatic cancer

Clinical study to investigate safety and efficacy on combination of gemcitabine and autologous gamma/delta T cell transfer therapy after resection of pancreatic cancer - Clinical study of gemcitabine and gamma/delta T cell therapy after resection of pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000931

Enrollment

Registered

2007-12-05

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Gamma/delta T cells are injected on day0, day14, day28, day42, day56, day70, day84, day98, day112, day126, day140, day154. Gemcitabine on day-3, day4, day11, day25, day32, day39, day53, day60, day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic cancer patients who have received curative resection: - No macroscopically and pathologically residual tumor (R0), or no macroscopically residual tumor (R1); - Life-expectancy is more than 3 months; - Performance status is 0-1; - No serious abnormality in bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Pulmonary fibrosis or interstitial pneumonia, or their history, or predisposition to them; - Active enteritis, autoimmune diseases, and/or infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Relapse rate (1 and 2 years) Relapse free survival Overall survival Survival rate (1 and 2 years) Response of tumor-related markers Immunological responses	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

The University of Tokyo, Graduate School of Medicine Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026